[go: up one dir, main page]

WO2022024097A1 - Compositions antivirales et leurs procédés d'utilisation - Google Patents

Compositions antivirales et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2022024097A1
WO2022024097A1 PCT/IB2021/057021 IB2021057021W WO2022024097A1 WO 2022024097 A1 WO2022024097 A1 WO 2022024097A1 IB 2021057021 W IB2021057021 W IB 2021057021W WO 2022024097 A1 WO2022024097 A1 WO 2022024097A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
vitamin
mushroom
terpenes
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2021/057021
Other languages
English (en)
Inventor
Stephen Barnhill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ai Pharmaceuticals Jamaica Ltd
Original Assignee
Ai Pharmaceuticals Jamaica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ai Pharmaceuticals Jamaica Ltd filed Critical Ai Pharmaceuticals Jamaica Ltd
Publication of WO2022024097A1 publication Critical patent/WO2022024097A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/071—Agaricus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A61K36/5775—Hibiscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • compositions having antiviral properties and methods of using them in the treatment or prevention of viral disease More particularly this relates to antiviral nutraceutical and/or pharmaceutical compositions comprising mushrooms or extracts thereof, cannabis extracts, terpenes, and flavonoids, and the like.
  • Antivirals unlike their early cousins, took decades longer to develop and reach a period of rapid development. The first antiviral compounds were recognized in the 1950s, however; even then the discovery of antivirals was rather empirical as the biological mechanism(s) by which antiviral compounds worked were not understood. As mechanisms were revealed and better tools were developed, the development path shortened, and better and less cytotoxic antiviral agents could be discovered.
  • mushrooms including psychedelic and non-psychedelic, medicinal and edible, as sources of healthful compounds as both food and drug.
  • psychedelic and non-psychedelic, medicinal and edible are sources of healthful compounds as both food and drug.
  • potentially therapeutic compounds present in mushrooms are complex sugars and polysaccharides (substituted or not) (e.g. glucans, glycosides, gly copeptides, and glycoproteins), terpenes and/or terpenoids, sterols, peptides, amino acids, and other small and large molecules.
  • compositions generally comprising combinations of one or more edible or medicinal mushrooms or an extract, fraction, or isolate thereof, one or more cannabinoids, one or more terpenes, and optionally, one or more flavonoids.
  • the mushroom or mushroom extract present in the compositions is from any edible or medicinal mushroom species.
  • the edible or medicinal mushroom in various embodiments comprises one or more of Agaricus blazei, A. bisporus, A. subrufescens, Agrocybe aegerita, A. cylindracea, Albatrellus caeruleoporus, Amanita muscaria, Boletus edulis, Cantharellus cibarius, C. tubaeformis, Cordyceps militaris, C. pruinose, Caripiaschiza, Cyathus africanus, C.
  • the cannabinoids can be derived from any Cannabis spp.
  • the terpenes and flavonoids can be derived from Cannabis or from any natural or synthetic source.
  • the compositions optionally include other nutraceutical or botanical compounds to provide additional functionality or support.
  • compositions comprising one or more edible or medicinal mushrooms, one or more cannabinoids, one or more terpenes, and at least one flavonoid with has many benefits for viral disease process treatment, and the compositions provide certain useful properties, such as effectiveness including over a long period of time, low toxicity, no serious side effects, and good tolerance on the part of a wide range of subjects.
  • compositions generally comprise one or more edible or medicinal mushrooms or an extract, fraction, or isolate thereof, one or more cannabinoids, one or more terpenes, and optionally, one or more flavonoids. Additional components can also be included, such as S-adenosylmethionine, methylfolate, omega-3 fatty acids, or a B vitamin, vitamin A, vitamin C, vitamin D, vitamin E, or a compound providing a biologically-available form thereof, or a variety of other nutraceutical or beneficial compounds or substances.
  • the disclosure also provides a plurality of dosing regimens that utilize the compositions, and variations thereof, on various schedules as dictated by the physiological or psychological health of the subject, and the status of the viral disease.
  • methods for optimizing a composition for use in treatment of a subject suffering from a viral disease process.
  • the methods generally employ the use of artificial intelligence algorithms, such as classification algorithms, regression algorithms, clustering algorithms, or a combination thereof.
  • the methods generally comprise:
  • compositions comprising one or more of mushrooms or extracts thereof, cannabinoids, terpenes, and flavonoid; or
  • the viral disease generally comprises a prevalent virus, or a virus for which other treatment options are limited or nonexistent.
  • the data for use in the artificial intelligence algorithm can be obtained from original experiments or literature review.
  • this disclosure provides methods for treating viral disease process in a patient in need thereof.
  • the methods generally comprise the step of administering a composition comprising at least one edible or medicinal mushroom or extract thereof, in combination with at least one cannabinoid, at least one terpene, and at least one flavonoid.
  • the at least one cannabinoid, at least one terpene, and at least one flavonoid are conveniently administered separately from, sequentially to, or simultaneously with the edible or medicinal mushroom.
  • the at least one edible or medicinal mushroom or extract thereof is also administered separately from, sequentially to, or simultaneously with the cannabinoid, terpene, and flavonoid.
  • compositions and methods for treating inflammation viral disease processes are applicable to acute or chronic viral infections, as well as latent viral diseases in a subject.
  • the compositions allow a modern practitioner to combine the benefits of certain compounds found in edible and medicinal mushrooms (such as used for centuries in Chinese and other traditional medicine practices, and by e.g. herbalists throughout the world), with the positive benefits of another natural substance, cannabis, also used for centuries.
  • the compositions further include certain beneficial terpenes and flavonoids derived from Cannabis and other natural or synthetic sources, and other nutraceutical or pharmaceutical compounds. Used properly, these compositions have little risk, few side effects, and are effective for producing measurable and lasting results in patients suffering from chronic inflammation or any viral disease process.
  • viral disease includes both acute and chronic viral infection, active and latent, and any diseases where the causation or symptomology substantially includes a viral infection including one that occurred at a time in the past.
  • Viral diseases / agents include, for example, smallpox, the common cold, influenza, parainfluenza, respiratory syncytial virus, adenovirus, measles, mumps, rubella, chicken pox /shingles, roseola, Chikungunya virus, Fifth disease, hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E, herpes and cold sores, polio, viral encephalitis, viral meningitis, rabies, Ebola, Lassa fever, yellow fever, Marburg hemorrhagic fever, Crimean- Congo hemorrhagic fever, Hanta fever, HIV, severe acute respiratory syndrome (SARS), Covid-19, Dengue fever, Zi
  • virus are often grouped by families, by means of transmission, or by their usual targets.
  • virus can be grouped as respiratory, gastrointestinal, hepatic, cutaneous, hemorrhagic, neurologic, and exanthematous, all of which are useful herein.
  • viruses listed above can be prevented by use of vaccines, while other virus for a variety of reasons are not susceptible to vaccines. Some virus are able to hid from the immune system, while other mutate quickly, still others can co-opt cellular machinery - even of immune system cells - and use that against the host. Some viruses have few symptoms and cause little harm to a host, while others are capable of causing great damage, or even killing their host. As we are learning, some viruses, such as coronavirus-SARS2, the causative agent of Covid-19, can do either - many people develop few or no symptoms and for others, it is fatal.
  • coronavirus-SARS2 the causative agent of Covid-19
  • the term "edible” does not mean merely capable of being eaten. In that overly broad sense, even poisonous or toxic mushrooms are 'edible' however lethal or sickening or the like. In contrast “edible mushrooms” is used herein in the sense of mushrooms that are used traditionally or in modern times as sources of food, nutrients, nutraceuticals, flavors, and the like. Edible mushrooms are neither toxic nor poisonous as consumed.
  • Medical mushrooms as used herein means any mushroom species that has been used traditionally or in modern times as a source of medicinal or therapeutic benefits, healing properties, and / or healthful compounds. It should be noted that the medicinal mushrooms may not be edible in all embodiments herein, and may in fact be poisonous if eaten, however, one or more extracts therefrom or components extracted or isolated therefrom may be perfectly useful herein.
  • mushrooms that are edible or medicinal may be grouped together, as there may be many crossovers and it may be difficult to clearly distinguish between the two groups.
  • Examples of edible and / or medicinal mushrooms useful herein include mushrooms of the genera Agaricus, Agrocybe, Albatrellus, Amanita, Antrodia, Auricularia, Boletus, Calvatia, Cantharellus, Caripia, Clitocybe, Cordyceps, Cyathus, Daldinia, Dictyophora, Elaphomyces, Flammulina, Pomes, Fomitopsis, Funalia, Ganoderma, Geastrum, Grifola, Hericium, Inocybe, Inonotus, Lactarius, Lentinus, Lentinula, Leucopaxillus,
  • Lyophyllum Phellinus, Pholiota, Pleurotus, Poria, Russula, Sarcodona, Schizophyllum, Suillus, Termitomyces, Trametes, or Xerocomus.
  • Species of particular interest include Agaricus blazei, A. bisporus, A. subrufescens, Agrocybe aegerita, A. cylindracea, Albatrellus caeruleoporus, Amanita muscaria, Boletus edulis, Cantharellus cibarius, C. tubaeformis, Cordyceps militaris, C.
  • pruinose Caripia commonlyi, Cyathus africanus, C. hookeri, Daldinia childiae, Dictyophora indusiata (synonym: Phallus indusiatus), Elaphomyces granulatus, Flammulina velutipes, Fomitopsis pinicola, Grifola frondosa, Ganoderma lucidum, Geastrum saccatum, Inonotus obliquus, Lactarius deliciosus, L. rufus, Lentinus edodes, L. polychrous, Lyophyllum decastes, Phellinus linteus, Pholiota nameko, Pleurotus pulmonarius, Poria cocos, and Termitomyces albuminosus.
  • More generally edible and / or medicinal mushrooms can be useful in connection with the current disclosure for treating inflammation, directly or indirectly.
  • the therapeutic uses may include: preventing and/or treating viral diseases, helping recover from antiviral treatments, particularly those with significant toxicity or side effects, stimulating and / or supporting the immune system, treating primary or secondary infections, or providing antibacterial or antifungal properties, reducing the side effects of other antiviral treatments, reducing or mitigating the psychological affects (e.g. stress, anxiety, or the like) of a serious viral disease, generally promoting of health, providing antioxidant functionality, reducing nausea or swelling, stimulating or promoting immune system health, or the like.
  • the psychological affects e.g. stress, anxiety, or the like
  • Reishi mushrooms have been reported to calm the central nervous system and/or have neuroprotective effect, stimulate the immune system, and act as a prebiotic to support gut health.
  • Reishi has been reported to have a beneficial effect on the adrenals, and to be anxiolytic; reducing anxiety and promoting sleep.
  • Reishi has also been associated with improved memory, and sharpened concentration and focus.
  • Lion's Mane reportedly calms mental activity and modulates certain neurotransmitters.
  • Cordyceps has been reported to have adaptagenic properties and stimulate the adrenals glands and modulates the nervous system. For purposes herein, the publication by Elsayed, Elsayed A et al.
  • “Cannabis” or “Cannabis spp.” as used herein refers to any plant of the genus Cannabis, including plants that may be classified as Cannabis sativa, Cannabis indica, or Cannabis ruderalis. It is well known that despite the foregoing list, some experts believe that there are only 2 species, and still others consider that there is only a single species (generally, C. sativa). Whatever nomenclature is used, for purposes of this disclosure, “Cannabis” includes all possible members of the genus, without regard to the species to which they are assigned.
  • 'cannabinoids means any of a class of compounds that generally can interact with one or more cannabinoid receptors, including the receptors of the endocannabinoid system, in particular, CB1 and CB2.
  • Cannabinoids include e.g., phytocannabinoids and synthetic cannabinoids.
  • Phytocannabinoids are found in several plant species, especially Cannabis spp. Among the most prevalent and most studied cannabinoids are tetrahydrocannabinol (THC), and cannabidiol (CBD).
  • cannabinoids that have been identified in Cannabis within certain classes including the tetrahydrocannabinols, cannabidiols, cannabigerols, cannabinols, cannabichromenes, and cannabinodiol.
  • Other cannabinoids such as cannabicyclol, cannabieslsoin, and cannabitriol are currently classed as 'miscellaneous' by some researchers.
  • THC is not only a major cannabinoid in Cannabis spp., it is generally the compound responsible for the psychoactive effects of consuming Cannabis.
  • compositions may be created with various ratios of cannabinoids, such as the ratio of CBD to THC or other ratios depending the specific person or the specific condition being treated.
  • curcuminoids means any of the compounds associated with turmeric or curcumin, as derived rhizome of the plant Curcuma longa, or synthetic versions or derivative thereof.
  • Curcuminoids include but are not limited to curcumin (aka diferuloylmethane), analogs of curcumin such as demethoxycurcumin (DMC), bisdemethoxycurcumin (BDMC), turmerones, and turmeric oil.
  • curcumin aka diferuloylmethane
  • analogs of curcumin such as demethoxycurcumin (DMC), bisdemethoxycurcumin (BDMC), turmerones, and turmeric oil.
  • metabolites of curcumin such as tetrahydrocurcumin (THCU), hexahydrocurcumin, and octahydrocurcumin.
  • Conjugates such as curcumin glucuronide and curcumin sulfate, are also included herein. Conjugation may also provide opportunities for improved delivery of curcumins herein, for example, conjugation to peptide carriers, or polylactic-co-gly colic acid [PLGA]; as well as complexation with essential oils; coadministration with piperine; and encapsulation into nanoparticles, liposomes, phytosomes, polymeric micelles, and cyclodextrins may also be useful herein.
  • curcumins for example, conjugation to peptide carriers, or polylactic-co-gly colic acid [PLGA]; as well as complexation with essential oils; coadministration with piperine; and encapsulation into nanoparticles, liposomes, phytosomes, polymeric micelles, and cyclodextrins may also be useful herein.
  • terpenes means any of the organic compounds commonly known as terpenes or terpenoids. Terpenes are generally aromatic compounds classified as isoprene derivatives. Terpenes suitable for use herein include hemiterpenes, monoterpenes, sesquiterpenes, diterpenes, sesterterpenes, triterpenes, sesquaterpenes, tetraterpenes, polyterpenes, and norisoprenoids.
  • Exemplary terpenes that are particularly useful herein include alpha bisabolol, alpha pinene, beta caryophyllene, beta pinene, borneol, camphor, camphene, caryophyllene, cineole, delta-3 carene, eucalyptol, farnesenes, farnesol, fenchol, fenchone, geraniol, guaiol, humulene, isopulegol, limonene, linalool, menthol, myrcene, nerol, nerolidol, ocimene, pinene, phytol, pulegone, terpinene, terpineol, terpinolene, and valencene.
  • phytol, limonene, humulene, myrcene, cineol, phellandrene, caryophyllene, terpinolene, linalool, ocimene, pinene, or a combination thereof are presently preferred.
  • flavonoids includes any of the class of polyphenolic molecules containing 15 carbon atoms that are naturally produced in plants and are soluble in water. Also included herein as “flavonoids” are natural or synthetic derivative or analogs thereof that have biological activity. Flavonoids of use herein can generally be divided in to 6 groups of structurally related compounds: chalcones, flavones, isoflavonoids, flavanones, anthoxanthins, and anthocyanins. Also useful are flavanols and catechins, as well as glucosides or other derivatives or analogs of any of the foregoing. The flavonoids are found in most fruits and vegetables, particular colorful ones. They are also prevalent in legumes (including soybeans), grains, green and black teas, as well as red wine.
  • Flavonoids have numerous functions in plants, and act as important cell messengers. Various flavonoids are believed to provide healthful benefits and functions to humans such as anti-viral, anti-cancer, anti-inflammatory, anti allergic, and anti-oxidant properties. They may also be cardio-protective, cholesterol-lowering, and anti- atherosclerotic. Natural or synthetic flavonoids from any source may be used herein. Generally natural flavonoids are preferred. Flavonoids isolated from Cannabis, such as cannaflavins A, B, and or C, are of interest in certain applications, as are vitexin, isovitexin, apigenin, kaempferol, quercetin, orientin, and luteolin, as well as the catechins found in Cannabis.
  • compositions or “a mushroom extract” includes a plurality of such “compositions” or “mushroom extracts.”
  • ranges are provided in shorthand, so as to avoid having to list and describe each and every value within the range. Any appropriate value within the range can be selected, where appropriate, as the upper value, lower value, or the terminus of the range.
  • APM "Apollon Medical” strain of C. sativa
  • CBD cannabidiol
  • CBG cannabigerol
  • DMT N, N -Dimethyl try ptamine ;
  • 5-HT 5-hydroxytryptamine
  • KNN K Nearest Neighbor
  • NK natural killer cells
  • NS AID nonsteroidal anti-inflammatory drugs
  • OCD obsessive compulsive disorder
  • SVM Support Vector Machines
  • THC tetrahydrocannabinol .
  • compositions generally comprising one or more edible or medicinal mushrooms or extracts, fractions, isolates, or components thereof are provided.
  • the compositions further generally comprise one or more cannabinoids, one or more terpenes, and optionally, one or more flavonoids.
  • the edible or medicinal mushroom(s) comprise one or more of the species Agaricus blazei, A. bisporus, A. subrufescens, Agrocybe aegerita, A. cylindracea, Albatrellus caeruleoporus, Amanita muscaria, Boletus edulis, Cantharellus cibarius, C. tubaeformis, Cordyceps militaris, C. pruinose, Caripia widelyi, Cyathus africanus, C.
  • Inonotus obliquus Lactarius deliciosus, L. rufus, Lentinus edodes, L. polychrous, Lyophyllum decastes, Phellinus linteus, Pholiota nameko, Pleurotus pulmonarius, Poria cocos, and Termitomyces albuminosus.
  • the mushroom(s) in other embodiments comprise one or more species such as Albatrellus confluens, Antrodia camphorate, Boletus badius, Clitocybe maxima, Cordyceps sinensis, Cordyceps liangshanensis, Cordyceps gunnii, Cordyceps cicadicola, Pomes fomentarius, Funalia trogii, Hericium erinaceus, Inocybe umbrinella, Lactarius flavidulus, Pleurotus ostreatus, Schizophyllum commune, Suillus placidus, or Trametes versicolor.
  • species such as Albatrellus confluens, Antrodia camphorate, Boletus badius, Clitocybe maxima, Cordyceps sinensis, Cordyceps liangshanensis, Cordyceps gunnii, Cordyceps cicadicola, Pomes fomenta
  • mushrooms are all well-known edible and / or medicinal mushrooms with a long history of use. Without limiting the invention to any particular theory of operation, mushrooms, such as Reishi, shitake, maitake, turkey tail, and many others have a plethora of beneficial and potentially therapeutic compounds present in them.
  • the polysaccharides, peptides, and/or other small molecules in various mushrooms have been shown to regulate the production of certain molecular mediators of inflammation and functions of immune cells (e.g. B- and/or T-cells) as well as pro-inflammatory lymphocytes, T-helper cells, T- killer cells, and macrophages.
  • immune cells e.g. B- and/or T-cells
  • the beta-1,3 D-glucans from certain mushrooms and other glycans may suppress cytokines such as interleukins tumor necrosis factor (TNF-a), and still other compounds
  • compositions preferably comprise the benefits of such edible or medicinal mushroom(s) as described above.
  • the edible or medicinal mushrooms or extracts can be present as fresh mushrooms, or as a dried mushroom or extract thereof, a lyophilized mushroom preparation, a mushroom powder, or an aqueous or alcohol extract (e.g. an ethanolic or other alcohol extract) of mushroom. Extracts for purposes herein can include hot- or cold-water extracts. Mushroom concentrates, or partially purified or even extensively purified mushroom fractions, or fully purified components or isolates from a mushroom are also useful herein.
  • various extracts, concentrates, or partially purified fractions, or the like are enriched for one or more advantageous mushroom component, or compounds with desirable effects on treatment of inflammation, immune status, or general health.
  • the extract, concentrate, partially purified fraction, or the like are enriched for one or more phenolic acids, flavonoids, triterpenes, carotenoids, stilbenes, sterols, fatty acids, lignans, chitosan, polyphenols, polysaccharides, glycosides, glucans, polysaccharide-protein complexes, glycoproteins, polysaccharopeptide, krestin, tocopherols, peptides, cyclic peptides, or other amino compounds found in the mushroom.
  • compositions in various embodiments therefor also include cannabinoids, comprising one or more of cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), or tetrahydrocannabinol (THC).
  • CBD cannabidiol
  • CBN cannabinol
  • CBG cannabigerol
  • THC tetrahydrocannabinol
  • the cannabinoids are derived from hemp, or the THC content is removed from the cannabinoids such that THC is present in the composition at less than about 0.3 percent. In various embodiments, the THC content may be less than 0.2, or even less than 0.1% of the composition.
  • the ratio of cannabinoids is set in the compositions.
  • the ratio of CBD to THC ranges from about 1:5 to about 30:1 or more. In other embodiments the ration may range from about 1:2 to about 10:1. In still other embodiments, the ratio of CBD to THC may be about 1:1 to 5:1. In other cases, the ration of e.g. CBD to CBG or CBN may be set based on any of a variety of factors, including the health status of the subject being treated, the symptoms of the subject, the condition(s) being treated, and or one or more physiological or genetic criteria.
  • the compositions may be provided in completely customized or personalized formulations for each person being treated - i.e. as personalized medicines.
  • the compositions may be adjusted based on initial or subsequent blood work, enzyme test results, bioinformatic data (including measurements of e.g. the genome, transcriptome, proteome, metabolome, or any portion thereof, for a subject), the nature of the inflammation, specific markers, antigen, or mediators of the viral disease process, specific symptomology, or the like.
  • the formulation of the compositions may also be changed based on the results from an initial treatment, subsequent treatment, or based on subsequent tests.
  • the cannabinoids are derived from Cannabis spp. or an extract thereof.
  • Cannabis can generally be concentrated or extracted (e.g. via mechanical or chemical means) to obtain cannabinoids.
  • Extraction via chemical means includes extraction with various volatile solvents that range from hydrocarbon solvents such as butane, hexanes, or propane, to supercritical fluids, alcohol (e.g. isopropanol, butanol, or ethanol), steam, or even water.
  • Two very common methods are extraction with supercritical carbon dioxide, or ethanol, both of which are particularly useful herein. Extracts can be also be distilled e.g. to remove additional compounds of interest, or to concentrate them.
  • Certain components can be removed, e.g. by treatment with steam to strip certain volatiles, which can be captured as an additional component from the Cannabis.
  • cannabinoids present in an ethanolic extract or supercritical C0 extract of Cannabis sativa are preferred for use herein.
  • the extract comprises one or more of Ringo's Gift, OG Kush, Strawberry Cough, Orange Cookies, Jack Herer-derived strains (e.g. Black Jack, Super Jack, Jl, and XJ13), and the Lemon family of strains of Cannabis sativa.
  • the extracts comprise Ringo's Gift, Harle Tsu, ACDC, Charlotte's Web, The Gift, or Pineberry strains. "Apollon Medical" (“APM”), a proprietary strain commercially available from Apollon Formularies, is also useful herein.
  • APM Polyon Medical
  • compositions include terpenes comprising one or more monoterpenes, one or more sesquiterpenes, or a combination thereof.
  • the terpenes generally comprise one or more of alpha bisabolol, alpha pinene, beta caryophyllene, beta pinene, borneol, camphor, camphene, caryophyllene oxide, cineole, delta-3 carene, eucalyptol, farnesenes, farnesol, fenchol, fenchone, geraniol, guaiol, humulene, isopulegol, limonene, linalool, menthol, myrcene, nerol, nerolidol, ocimene, pinene, phytol, pulegone, terpinene, terpineol, terpinolene, or valencene.
  • the terpenes comprise phytol, limonene, humulene, myrcene, cineol, phellandrene, caryophyllene, terpinolene, linalool, ocimene, pinene, or a combination thereof.
  • the terpenes preferably comprise one or more of limonene, myrcene, beta-caryophyllene, linalool, alpha pinene, or a combination thereof.
  • the terpenes include beta- ocimene, 1,8-cineole, alpha-pinene and / or beta-pinene, linalool, limonene, phytol, humulene, myrcene, phellandrene, caryophyllene, terpinolene, linalool, or other cineols or ocimenes, or any combination thereof, and the strains used to isolate terpenes are high in those terpenes, relative to other strains.
  • the terpenes are derived from Cannabis spp. or an extract thereof.
  • the terpenes can be derived from any source and in certain embodiments, they can be present in steam distillate or an ethanolic extract of Cannabis sativa.
  • compositions in certain embodiments include extracts of Cannabis spp, such as C. sativa as a source of cannabinoids and/or terpenes.
  • the C. sativa comprises one or more of Ringo's Gift, OG Kush, Strawberry Cough, Orange Cookies, Jack Herer-derived strains, Lemon family strains, Harle Tsu, ACDC, Charlotte's Web, The Gift, or Pineberry strains.
  • the C. sativa comprises the proprietary Apollon Formularies strain, APM.
  • the compositions may further comprise one or more flavonoids.
  • the flavonoids can comprise chalcones, flavones, isoflavonoids, flavanones, anthoxanthins, anthocyanins, flavonols, or glucosides or other biologically active derivatives or analogs thereof, and combinations of any number of the foregoing.
  • flavonoids are included in the compositions are isolated or derived from a plant, mushroom, or other natural source.
  • the composition still further comprises an extract or fraction from one or more traditional Jamaican medicinal plants other than Cannabis spp..
  • Any of the traditional Jamaican or Carribbean medicinal plants may be useful herein.
  • Jamaican plants useful herein include ackee, aloe vera, avocado, breadflower, ginger, leaf of life, sorrel, soursop, tamarind, and trumpet.
  • the traditional medicinal plants comprise Jamaican sorrel ( Hibiscus sabdariffa), guinea hen weed ( Petiveria alliacea), and/or soursop ( Annona murata).
  • the compositions include a whole plant extract, or an extract from any parts or portion thereof including but not limited to leaves (dried, fresh, or extracted), stems, flowers, roots, fruit, seeds, or the like.
  • compositions In terms of compounding the compositions, the skilled artisan will appreciate that methods of maximizing the efficacy of the composition such as by enhancing the bioavailability of one or more components, or by providing the components in optimized ratios, for example one component to another with which it interacts, or each component to the others in ratio(s) that optimize the absorption into the gut or bloodstream, or enhance the therapeutic effect of the composition. The skilled artisan will also understand that some information useful in improving the compounding may be obtained empirically.
  • compositions, or one or more components thereof may be solubilized, micronized, provided as, for example, extracts, powders, lyophilized powders, concentrates, tinctures, essential oils, aqueous or lipid suspensions, emulsions, microemulsions, or nano-emulsions, or in whole or part as liposomal, vesicular, or other delivery systems.
  • extracts, powders, lyophilized powders concentrates, tinctures, essential oils, aqueous or lipid suspensions, emulsions, microemulsions, or nano-emulsions, or in whole or part as liposomal, vesicular, or other delivery systems.
  • aqueous or lipid suspensions emulsions, microemulsions, or nano-emulsions, or in whole or part as liposomal, vesicular, or other delivery systems.
  • the compounding or formulation of any of the compositions provided herein may be optimized for the intended delivery route
  • compositions may be administered and delivered as pharmaceuticals, however, it is also contemplated that one or more of the compositions may be formulated for administration and delivery by oral routes that include as food and beverages, including solid, semisolid, and liquid foods, such as smoothies, shakes, pudding, broths, teas, and soups.
  • food and or beverage compositions can also include hot, cold, or even frozen foods (such as frozen desserts).
  • kits for treating a subject suffering from inflammation comprising administering a therapeutically effective dose of a composition to the subject.
  • the composition typically comprises one or more edible or medicinal mushrooms or an extract, fraction, or isolate thereof, one or more cannabinoids, one or more terpenes, and optionally, one or more flavonoids.
  • the inflammation in various embodiments comprises a viral disease, such as.
  • composition for use in the methods is generally as described above for the first aspect.
  • description of the compositions above is incorporated by reference herein for purposes of the present methods.
  • compositions for use in the methods further comprise one or more optional ingredients comprising S-adenosylmethionine, methylfolate, omega-3 fatty acids, or a B vitamin, vitamin A, vitamin C, vitamin D, vitamin E, or a compound providing a biologically-available form thereof.
  • fish oil primrose oil, or an extract of one or more of black cumin, Echinacea, Astralagus, sorrel, ginger, ginseng, bee propolis, bee pollen, honey, fenugreek, goldenseal, licorice, coriander, tomato, carrot, sweet potato, broccoli, green tea, rosemary, hazelnut, walnut, wheat germ, pomegranate, or date, or any combination thereof, can also be included.
  • Garlic extract alpha lipoic acid (ALA), conjugated linoleic acid (CLA), phytoestrogens, soy isoflavones, selenium, zinc, copper, magnesium, niacin, and/or nicotinamide are also contemplated for use herein.
  • ALA alpha lipoic acid
  • CLA conjugated linoleic acid
  • phytoestrogens soy isoflavones
  • selenium zinc, copper, magnesium, niacin, and/or nicotinamide
  • the terpenes for use with the compositions can comprise one or more monoterpenes, one or more sesquiterpenes, or a combination thereof.
  • the terpenes comprise one or more of alpha bisabolol, alpha pinene, beta caryophyllene, beta pinene, borneol, camphor, camphene, caryophyllene oxide, cineole, delta-3 carene, eucalyptol, farnesenes, farnesol, fenchol, fenchone, geraniol, guaiol, humulene, isopulegol, limonene, linalool, menthol, myrcene, nerol, nerolidol, ocimene, pinene, phytol, pulegone, terpinene, terpineol, terpinolene, or valencene.
  • the terpenes can comprise beta- ocimene, 1,8-cineole, alpha-pinene and / or beta-pinene, linalool, limonene, phytol, humulene, myrcene, phellandrene, caryophyllene, terpinolene, linalool, or other cineols or ocimenes, or any combination thereof,
  • the terpenes are derived from Cannabis spp. or an extract thereof.
  • the terpenes can be present in steam distillate or an ethanolic extract of Cannabis sativa, and can comprise limonene, myrcene, beta- caryophyllene, linalool, alpha pinene, or a combination thereof, in some embodiments.
  • the Cannabis sativa in one embodiment includes one or more of Ringo's Gift, OG Kush, Strawberry Cough, Orange Cookies, Jack Herer-derived strains (e.g. Black Jack, Super Jack, Jl, and XJ13), and the Lemon family of strains of Cannabis sativa.
  • Ringo's Gift, Harle Tsu, ACDC, Charlotte's Web, The Gift, or Pineberry strains are useful.
  • compositions for use with the methods also comprise one or more flavonoids that can be chalcones, flavones, isoflavonoids, flavanones, anthoxanthins, anthocyanins, flavonols, or glucosides or other biologically active derivatives or analogs thereof, and preferably they are from a plant, mushroom, or other natural source.
  • flavonoids can be chalcones, flavones, isoflavonoids, flavanones, anthoxanthins, anthocyanins, flavonols, or glucosides or other biologically active derivatives or analogs thereof, and preferably they are from a plant, mushroom, or other natural source.
  • presently preferred flavonoids include cannaflavin A, cannaflavin B, or cannaflavin C, vitexin, isovitexin, apigenin, kaempferol, quercetin, orientin, luteolin, a catechin found in Cannabis, or a combination of any of the foregoing.
  • the methods further comprise one or more steps of administering an additional therapeutically effective dose of the composition.
  • the additional administering steps are performed on a periodic basis of any frequency or schedule.
  • the administration or dosing can conveniently be on e.g. a daily, thrice weekly, twice weekly, weekly, biweekly, monthly, bimonthly, quarterly, semi-annual, or annual basis.
  • the administration need not be the same over every period of time.
  • administration could be daily for a week, then weekly for a month.
  • the administration could be every 4 months for a year, then every 6 months thereafter.
  • the actual amount of the composition or dosage administration can vary.
  • a monthly dosage schedule could feature a dose of x for the first dosage each quarter, and a dose of O.lx for the remaining months in each quarter.
  • the methods further comprise the step of periodically assessing one or more of the subject's medication levels, enzyme levels, or other indicators of physiological health or status, genetic markers or metabolic markers or mediator presence, or the like, in order to determine the periodic basis for administration.
  • compositions via any useful route, including parenteral (intravenous, intra-arterial, intramuscular, intraperitoneal, or subcutaneous), oral, nasal, ocular, transmucosal (buccal, vaginal, or rectal), transdermal, or via inhalation.
  • parenteral intravenous, intra-arterial, intramuscular, intraperitoneal, or subcutaneous
  • oral nasal, ocular
  • transmucosal bonal, vaginal, or rectal
  • transdermal or via inhalation.
  • the route of dosing or administration of compositions can vary over the course of treating a subject or patient with multiple steps of treatment, as well as from subject to subject, or with different types of viral disease.
  • administration via one route may be useful when administering a larger dose and a different route may be useful for smaller doses.
  • administration via a particular route may be appropriate initially, with subsequent doses conveniently administered through another route.
  • the method further comprises a step of providing to the subject additional treatment of the viral disease comprising: i) one or more doses of an antiviral pharmacological agent; ii) one or more doses of an antibiotic; iii) one or more treatments to reduce the severity or duration of the viral disease process; iv) one or more other treatments specifically provided to support the subject during recovery from the viral disease process; or any combination of any of the foregoing.
  • compositions that further comprise a step of providing to the subject an additional composition are also provided.
  • the additional composition may be administered in between doses of the base compositions, or may be provided on a separate and independent periodic basis.
  • the addition compositions generally comprise any combination of less than three of the following:
  • compositions further optionally comprise any combination of one or more of S-adenosylmethionine, methylfolate, omega-3 fatty acids, or a B vitamin, vitamin A, vitamin C, vitamin D, vitamin E, or a compound providing a biologically-available form thereof.
  • the one or more edible or medical mushrooms comprise Agaricus
  • Phellinus Pholiota, Pleurotus, Poria, Russula, Sarcodona, Schizophyllum, Suillus, Termitomyces, Trametes, or Xerocomus;
  • the cannabinoids comprise one or more of cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), or tetrahydrocannabinol (THC);
  • CBD cannabidiol
  • CBN cannabinol
  • CBG cannabigerol
  • THC tetrahydrocannabinol
  • the terpenes comprise one or more of alpha bisabolol, alpha pinene, beta caryophyllene, beta pinene, borneol, camphor, camphene, caryophyllene oxide, cineole, delta-3 carene, eucalyptol, farnesenes, farnesol, fenchol, fenchone, geraniol, guaiol, humulene, isopulegol, limonene, linalool, menthol, myrcene, nerol, nerolidol, ocimene, pinene, phytol, pulegone, terpinene, terpineol, terpinolene, or valencene; and
  • the one or more flavonoids comprise chal cones, flavones, isoflavonoids, flavanones, anthoxanthins, anthocyanins, flavonols, or glucosides or other biologically active derivatives or analogs thereof.
  • the terpenes preferably comprise beta-ocimene, 1,8- cineole, alpha-pinene and/or beta-pinene, linalool, limonene, phytol, humulene, myrcene, phellandrene, caryophyllene, terpinolene, linalool, or other cineols or ocimenes, or any combination thereof.
  • the viral disease process can comprise any of smallpox, the common cold, influenza, parainfluenza, respiratory syncytial virus, adenovirus, measles, mumps, rubella, chicken pox/ shingles, roseola, Chikungunya virus, Fifth disease, hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E, herpes and cold sores, polio, viral encephalitis, viral meningitis, rabies, Ebola, Lassa fever, yellow fever, Marburg hemorrhagic fever, Crimean-Congo hemorrhagic fever, Hanta fever, HIV, severe acute respiratory syndrome (SARS), Covid-19, Dengue fever, Zika, Epstein-Barr, human papilloma virus (HPV), rotavirus, norovirus, astrovirus, genital warts, genital herpes, molluscum contagiosum
  • the composition further comprises an extract or fraction from one or more traditional Jamaican medicinal plants other than Cannabis spp.
  • the traditional medicinal plants comprise Jamaican sorrel
  • Hibiscus sabdariffa Hibiscus sabdariffa
  • guinea hen weed Petiveria alliacea
  • soursop Annona murata
  • methods of optimizing a composition for use in treatment of a subject suffering from viral disease process using artificial intelligence are provided herein.
  • the methods generally comprise, for each viral disease process of interest, or for a subject in need of therapeutic compositions for such viral disease process:
  • compositions comprising one or more of mushrooms or extracts thereof, cannabinoids, terpenes, and flavonoid; or
  • the viral disease process comprises smallpox, the common cold, influenza, parainfluenza, respiratory syncytial virus, adenovirus, measles, mumps, rubella, chicken pox/ shingles, roseola, Chikungunya virus, Fifth disease, hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E, herpes and cold sores, polio, viral encephalitis, viral meningitis, rabies, Ebola, Lassa fever, yellow fever, Marburg hemorrhagic fever, Crimean-Congo hemorrhagic fever, Hanta fever, HIV, severe acute respiratory syndrome (SARS), Covid-19, Dengue fever, Zika, Epstein-Barr, human papilloma virus (HPV), rotavirus, norovirus, astrovirus, genital warts, genital herpes, molluscum conta
  • the artificial intelligence algorithm can comprise any useful software or algorithm approach capable of making the distinctions required.
  • the algorithm comprises a classification algorithm, a regression algorithm, a clustering algorithm, or a combination thereof.
  • the methods comprise a classification algorithm that is a naive Bayes algorithm, decision tree, random forest algorithm, Support Vector Machines, or K Nearest Neighbor algorithm.
  • the methods comprise a regression algorithm that is a liner regression, lasso regression, logistic regression, or multivariate regression.
  • the methods comprise a clustering algorithm that is a K-means clustering, fuzzy C-means algorithm, expectation-maximization algorithm, or hierarchical clustering algorithm.
  • a clustering algorithm that is a K-means clustering, fuzzy C-means algorithm, expectation-maximization algorithm, or hierarchical clustering algorithm.
  • the methods comprising the additional step of providing subject-specific data comprising, e.g. initial or subsequent blood work, enzyme test results, bioinformatic data (including measurements of e.g. the genome, transcriptome, proteome, metabolome, or any portion thereof, for a subject), specific symptomology, or the like.
  • subject-specific data comprising, e.g. initial or subsequent blood work, enzyme test results, bioinformatic data (including measurements of e.g. the genome, transcriptome, proteome, metabolome, or any portion thereof, for a subject), specific symptomology, or the like.
  • the artificial intelligence algorithm is then used to further optimize the composition based on those data in addition to the disorder-specific data.
  • the optimized formulation of the compositions may also be changed based on data from the results from an initial treatment, subsequent treatment, or based on subsequent tests of the subject.
  • the viral disease process comprises a prevalent form of viral disease process such as smallpox, the common cold, influenza, parainfluenza, respiratory syncytial virus, adenovirus, measles, mumps, rubella, chicken pox/ shingles, roseola, Chikungunya virus, Fifth disease, hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E, herpes and cold sores, polio, viral encephalitis, viral meningitis, rabies, Ebola, Lassa fever, yellow fever, Marburg hemorrhagic fever, Crimean-Congo hemorrhagic fever, Hanta fever, HIV, severe acute respiratory syndrome (SARS), Covid-19, Dengue fever, Zika, Epstein-Barr, human papilloma virus (HPV), rotavirus, norovirus, astrovirus, genital warts, gen
  • the plurality of edible or medicinal mushrooms, mushroom extracts, or components for which data are analyzed generally comprise one or more of the species Agaricus blazei, Albatrellus confluens, Antrodia camphorate, Boletus badius, Clitocybe maxima, Cordyceps militaris, Flanulina velutipes, Fomes fomentarius, Funalia trogii, Ganoderma lucidum, Grifoloa fondosa, Hericium erinaceus, Inocybe umbrinella, Ionatus olbiquus, Lactarius flavidulus, Lentinula edodes, Phellinus linteus, Pleurotus ostreatus, Schizophyllum commune, Suillus placidus, Trametes versicolor, Cordyceps sinensis, C.
  • a further aspect of the invention provides methods for the treatment of viral disease process.
  • the methods generally comprise the step of administering to a patient in need thereof a composition comprising at least one edible or medicinal mushroom or extract thereof, in combination with at least one cannabinoid, at least one terpene, and at least one flavonoid.
  • the at least one cannabinoid, at least one terpene, and at least one flavonoid are administered separately from, sequentially to, or simultaneously with the edible or medicinal mushroom or extract thereof.
  • the at least one edible or medicinal mushroom or extract thereof is also administered separately from, sequentially to, or simultaneously with the cannabinoid, terpene, and flavonoid.
  • composition with respect to this aspect of the disclosure can comprise any of the compositions described hereinabove.
  • the at least one edible or medicinal mushroom or extract comprises comprise Agaricus blazei, Albatrellus confluens, Antrodia camphorate, Boletus badius, Clitocybe maxima, Cordyceps militaris, Flanulina velutipes, Fomes fomentarius, Funalia trogii, Ganoderma lucidum, Grifoloa fondosa, Hericium erinaceus, Inocybe umbrinella, Ionatus olbiquus, Lactarius flavidulus, Lentinula edodes, Phellinus linteus, Pleurotus ostreatus, Schizophyllum commune, Suillus placidus, Trametes versicolor, Cordyceps sinensis, C. liangshanensis, C. gunnii, or C. cicadicola, ⁇
  • the at least one cannabinoid comprises CBD, CBG, CBN, and THC extracted from Cannabis sativa Ringo's Gift, OG Kush, Strawberry Cough, Orange Cookies, Jack Herer-derived strains, Lemon family strains, Harle Tsu, ACDC, Charlotte's Web, The Gift, or Pineberry strains;
  • the at least one terpene comprises beta-ocimene, 1,8-cineole, alpha- pinene and / or beta-pinene, linalool, limonene, phytol, humulene, myrcene, phellandrene, caryophyllene, terpinolene, linalool, or other cineols or ocimenes, or any combination thereof; and
  • the at least one flavonoid comprises a chalcone, flavone, isoflavonoid, flavanone, anthoxanthin, anthocyanin, flavonol, or glucoside or other biologically active derivatives or analogs thereof.
  • one or more of the components have one more of the following functions: [137] i) induces apoptosis of cells involved viral disease process;
  • [142] vi) allows one or more immune T-cells or B-cells to neutralize the virus.
  • the composition further comprises an extract or fraction from one or more traditional Jamaican medicinal plants other than Cannabis spp.
  • Traditional medicinal plants such as Jamaican sorrel ( Hibiscus sabdariffa), guinea hen weed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions et des procédés pour le traitement de divers processus pathologiques viraux. Les compositions comprennent généralement au moins un champignon comestible ou médicinal ou un extrait de celui-ci, au moins un cannabinoïde, au moins un terpène et au moins un flavonoïde. L'invention concerne également des procédés d'optimisation de compositions à l'aide d'algorithmes d'intelligence artificielle.
PCT/IB2021/057021 2020-07-31 2021-08-01 Compositions antivirales et leurs procédés d'utilisation Ceased WO2022024097A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063059970P 2020-07-31 2020-07-31
US63/059,970 2020-07-31

Publications (1)

Publication Number Publication Date
WO2022024097A1 true WO2022024097A1 (fr) 2022-02-03

Family

ID=80035390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/057021 Ceased WO2022024097A1 (fr) 2020-07-31 2021-08-01 Compositions antivirales et leurs procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2022024097A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113174338A (zh) * 2021-05-28 2021-07-27 广西壮族自治区农业科学院 一种黑木耳组织分离培养基及其应用
CN115725420A (zh) * 2022-10-12 2023-03-03 黑龙江省农业科学院经济作物研究所 一株产黄酮类化合物的工业大麻内生真菌及其应用
US11998515B1 (en) 2023-04-24 2024-06-04 King Faisal University Enhancement of curcumin plasma levels using eucalyptol co-administration
CN120555200A (zh) * 2025-05-23 2025-08-29 广东丸美生物技术股份有限公司 双向发酵的方法、荔枝加工副产物发酵物、化妆品

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170112885A1 (en) * 2010-12-01 2017-04-27 Gowey Research Group, Pllc Herbal formulations of carnivorous plants and methods for treating inflammation
US20180193403A1 (en) * 2015-07-06 2018-07-12 Cg-Bio Genomics, Inc. Healthful supplements
WO2019036243A1 (fr) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
US20200229411A1 (en) * 2016-08-21 2020-07-23 Insectergy, Llc Insect production systems and methods
WO2021003091A1 (fr) * 2019-07-03 2021-01-07 Vertosa Inc. Infusion d'ingrédients actifs hydrophobes émulsifiés dans des boissons à haute teneur en polyphénols

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170112885A1 (en) * 2010-12-01 2017-04-27 Gowey Research Group, Pllc Herbal formulations of carnivorous plants and methods for treating inflammation
US20180193403A1 (en) * 2015-07-06 2018-07-12 Cg-Bio Genomics, Inc. Healthful supplements
US20200229411A1 (en) * 2016-08-21 2020-07-23 Insectergy, Llc Insect production systems and methods
WO2019036243A1 (fr) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
WO2021003091A1 (fr) * 2019-07-03 2021-01-07 Vertosa Inc. Infusion d'ingrédients actifs hydrophobes émulsifiés dans des boissons à haute teneur en polyphénols

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROSENBERG ET AL.: "Cannabinoids and Epilepsy", NEUROTHERAPEUTICS, vol. 12, 2015, pages 747 - 768, XP036033960, DOI: 10.1007/s13311-015-0375-5 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113174338A (zh) * 2021-05-28 2021-07-27 广西壮族自治区农业科学院 一种黑木耳组织分离培养基及其应用
CN113174338B (zh) * 2021-05-28 2022-12-20 广西壮族自治区农业科学院 一种黑木耳组织分离培养基及其应用
CN115725420A (zh) * 2022-10-12 2023-03-03 黑龙江省农业科学院经济作物研究所 一株产黄酮类化合物的工业大麻内生真菌及其应用
US11998515B1 (en) 2023-04-24 2024-06-04 King Faisal University Enhancement of curcumin plasma levels using eucalyptol co-administration
CN120555200A (zh) * 2025-05-23 2025-08-29 广东丸美生物技术股份有限公司 双向发酵的方法、荔枝加工副产物发酵物、化妆品

Similar Documents

Publication Publication Date Title
WO2022024097A1 (fr) Compositions antivirales et leurs procédés d'utilisation
Aghababaei et al. Recent advances in potential health benefits of quercetin
Mohd Zaid et al. Promising natural products in new drug design, development, and therapy for skin disorders: An overview of scientific evidence and understanding their mechanism of action
CA3186850A1 (fr) Compositions et methodes de traitement de cancers
Ansori et al. Medicinal properties of Muntingia calabura L.: A Review
CA2980173C (fr) Activite antivirale de champignons medicinaux contenant des composes de carboxylate de phenyle et d'acrylate de phenyle
WO2022024096A1 (fr) Compositions et procédés pour favoriser la perte de poids et pour le traitement de l'obésité
US20240091292A1 (en) Methods for treatment of human cancers using cannabis compositions
Zhumaliyeva et al. Natural compounds of Salvia L. genus and molecular mechanism of their biological activity
Zhao et al. Antidepressant-like effect of Ganoderma lucidum spore polysaccharide-peptide mediated by upregulation of prefrontal cortex brain-derived neurotrophic factor
Badalyan et al. Mushrooms as promising therapeutic resources: review and future perspectives
WO2022091051A1 (fr) Compositions et émulsions de cannabis
WO2022091061A1 (fr) Compositions de cannabis et nanoémulsions
KR20230005129A (ko) 코로나바이러스 감염을 치료 및 예방하기 위한 조성물 및 방법
Alavinezhad et al. Zataria multiflora extract influenced asthmatic patients by improving respiratory symptoms, pulmonary function tests and lung inflammation
JP2025148423A (ja) 宿主防御機構の恒常性の調節用の標準化バイオフラボノイド組成物
Martinez-Burgos et al. Bioactive compounds produced by macromycetes for application in the pharmaceutical sector: Patents and products
CA3187534A1 (fr) Compositions et procedes pour le traitement d'une inflammation
Booi et al. Medicinal mushrooms for respiratory health
Araya-Sibaja et al. Hybrid nanoparticles of proanthocyanidins from Uncaria tomentosa leaves: QTOF-ESI MS characterization, antioxidant activity and immune cellular response
WO2022091050A1 (fr) Compositions pour le traitement de la cystite interstitielle et d'autres maladies de la vessie
CA3203361A1 (fr) Compositions comprenant des extraits de cannabis et de champignons, et leurs utilisations
Hussein et al. Biochemical, enzymatic, and immunological study on antimutagenic Achillea millefolium methanolic extract in vivo
Gupta et al. Review on phytochemicals and pharmacological activities of Boerhaavia diffusa Linn.
Mishra et al. Nutraceuticals as Immunomodulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21851082

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21851082

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 21/09/2023)

122 Ep: pct application non-entry in european phase

Ref document number: 21851082

Country of ref document: EP

Kind code of ref document: A1